| Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. | |
| | |
MedLine Citation:
|
PMID: 22563085 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Red blood cell transfusions have reduced morbidity and mortality for patients with sickle cell disease. Transfusions can lead to erythrocyte alloimmunization, however, with serious complications for the patient including life-threatening delayed hemolytic transfusion reactions and difficulty in finding compatible units, which can cause transfusion delays. In this review, we discuss the risk factors associated with alloimmunization with emphasis on possible mechanisms that can trigger delayed hemolytic transfusion reactions in sickle cell disease, and we describe the challenges in transfusion management of these patients, including opportunities and emerging approaches for minimizing this life-threatening complication. |
| | |
Authors:
|
Karina Yazdanbakhsh; Russell E Ware; France Noizat-Pirenne |
Related Documents
:
|
22737075 - Highly efficient prion transmission by blood transfusion. 9500245 - Clinical evaluation of the new pall leucocyte-depleting blood cardioplegia filter (bc1). 1520635 - The screening for common drugs of abuse in whole blood by means of emit-ets and fpia-ad... 12932095 - Storage duration and polymerase chain reaction detection of plasmodium falciparum from ... 26185 - Skeletal muscle po2: indicator of peripheral tissue perfusion in haemorrhagic shock. 21714135 - Changes of circulatory-metabolic indices and skull biomechanics with brain activity dur... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review Date: 2012-05-04 |
Journal Detail:
|
Title: Blood Volume: 120 ISSN: 1528-0020 ISO Abbreviation: Blood Publication Date: 2012 Jul |
Date Detail:
|
Created Date: 2012-07-23 Completed Date: 2012-10-02 Revised Date: 2013-04-16 |
Medline Journal Info:
|
Nlm Unique ID: 7603509 Medline TA: Blood Country: United States |
Other Details:
|
Languages: eng Pagination: 528-37 Citation Subset: AIM; IM |
Affiliation:
|
Laboratory of Complement Biology, New York Blood Center, 310 East 67th St, NewYork, NY 10065, USA. kyazdanbakhsh@nybloodcenter.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anemia, Sickle Cell
/
epidemiology,
immunology*,
physiopathology Blood Group Incompatibility / immunology* Blood Transfusion* Erythrocytes / immunology* Humans Isoantigens / immunology* Risk Factors |
| Grant Support | |
ID/Acronym/Agency:
|
R21 HL097350/HL/NHLBI NIH HHS; R21HL097350/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Isoantigens |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in...
Next Document: Plasminogen is a key pro-inflammatory regulator that accelerates the healing of acute and diabetic w...